Clinical Research Details

Clinical Research

A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Study Description

This study is for individuals who have Crohn’s disease (CD). The purpose of this research study is to compare the effects of the study drugs, PF-06651600 and PF-06700841, with a placebo (a preparation made to look like the study drug but that has no activity, like a sugar pill) to find out if PF-06651600 and PF-06700841 may be effective for treating CD.

PF-06651600 and PF-06700841 are investigational drugs. An investigational drug is one that is not approved for sale in this country. You may be in this research study for about 74 weeks. You will need to visit the research site at least 15 times (including the first screening visit) during the study. The study doctor may schedule visits (unplanned visits) in addition to those listed on the schedule of activities, in order to conduct evaluations or assessments to protect your well-being.

Open Enrollment

Contact Name: Kelly Jackman
Contact Phone: (904) 633-0070
Contact Email: kelly.jackman@jax.ufl.edu

Investigators


Principal Investigator
Ron Schey, M.D.
Medicine

Sub Investigator
Maged P. Ghali, M.D.
Medicine